Press-release for stocks related to covid for LLY

Prices are updated after-hours

tags : Covid symbols : LLY

save search

FDA Approves Eli Lily's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 157.67% | O: -3.03% H: 0.0% C: 0.0%
covid-19 fda olumiant covid

Global Lumakras Drug Market By Therapy Type, Disease Indication, and Region (Including COVID-19 Impact Analysis): A Report by Absolute Markets Insights
Published: 2022-03-14 (Crawled : 16:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 182.47% | O: 1.01% H: 0.71% C: 0.0%
RVMD | $35.56 -1.93% -1.97% 1.2M

Health Technology

| 76.54% | O: 0.15% H: 0.72% C: -9.31%
MRNA | News S | $108.82 0.86% 0.85% 3.4M

Health Technology

| -21.24% | O: 1.45% H: 18.94% C: 7.04%
MRTX | $58.7 -0.17% 0.34% 0

Health Technology

| -27.18% | O: -0.78% H: 3.11% C: -5.4%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

Health Technology

| 19.98% | O: 1.34% H: 0.0% C: 0.0%
covid-19 lumakras drug covid disease report therapy

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 214.08% | O: -2.3% H: 1.23% C: 0.29%
VERU | $1.325 3.92% 3.77% 1.5M

Health Technology

| -79.25% | O: -0.47% H: 5.06% C: -4.11%
covid-19 covid report phase 3 sabizabulin

Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Published: 2022-02-11 (Crawled : 21:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| Email alert Add to watchlist
covid-19 treatment covid authorization merge emergency use authorization

Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
Published: 2022-02-10 (Crawled : 23:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 213.79% | O: -0.09% H: 0.0% C: 0.0%
covid-19 treatment ongoing covid

BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
Published: 2022-01-27 (Crawled : 07:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 216.24% | O: 0.89% H: 1.37% C: -1.36%
covid-19 trial covid

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
Published: 2021-12-03 (Crawled : 22:00) - biospace.com/
ABCL | $3.9 -1.76% -1.79% 1.6M

| -72.84% | O: 3.41% H: 0.0% C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 205.08% | O: 2.15% H: 0.0% C: 0.0%
covid therapy authorized antibody merge

Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12
Published: 2021-12-03 (Crawled : 20:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| Email alert Add to watchlist
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| Email alert Add to watchlist
covid therapy authorized antibody merge

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
Published: 2021-11-02 (Crawled : 23:00) - biospace.com/
ABCL | $3.9 -1.76% -1.79% 1.6M

| -77.1% | O: -0.41% H: 5.54% C: 4.54%
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 194.73% | O: -1.55% H: 0.0% C: 0.0%
covid treatment

Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| -9.27% | O: 0.26% H: 2.0% C: 1.15%
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 194.73% | O: -1.55% H: 0.0% C: 0.0%
covid treatment

Global Immunotherapy Drugs Markets 2021-2026 - Launch of NG Immunotherapies / COVID-19 as Growth Catalyst / Approval of Novel Immunotherapy Drugs / Surge in Adoption of Car T-Cell Therapies
Published: 2021-10-28 (Crawled : 18:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 200.68% | O: -0.0% H: 2.63% C: 1.28%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -4.29% | O: 0.83% H: 1.2% C: 0.32%
covid immunotherapy therapy drug growth approval t-cell car-t

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
Published: 2021-09-21 (Crawled : 19:00) - biospace.com/
ABCL | $3.9 -1.76% -1.79% 1.6M

| -81.11% | O: -0.58% H: 3.16% C: 2.68%
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 230.74% | O: 2.04% H: 0.72% C: -0.81%
covid treatment

Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19
Published: 2021-09-21 (Crawled : 18:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| -9.37% | O: 0.71% H: 0.83% C: -0.05%
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 230.74% | O: 2.04% H: 0.72% C: -0.81%
covid treatment europe

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| Email alert Add to watchlist
covid expansion merge authorized emergency use authorization

Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| -10.45% | O: 0.14% H: 0.49% C: -0.26%
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 221.83% | O: 0.15% H: 0.26% C: -1.3%
covid merge authorized emergency use authorization

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
ABCL | $3.9 -1.76% -1.79% 1.6M

| -79.27% | O: -0.11% H: 5.8% C: 5.38%
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 221.83% | O: 0.15% H: 0.26% C: -1.3%
covid fda merge authorized emergency use authorization

Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19
Published: 2021-09-15 (Crawled : 11:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 222.71% | O: 0.21% H: 2.48% C: 0.06%
covid treatment covid-19

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 191.23% | O: 0.1% H: 0.09% C: -0.44%
RIGL | $1.125 -1.32% -1.33% 6.4M

Health Technology

| -70.26% | O: -0.26% H: 8.84% C: 8.44%
covid disease phase 2 infectious disease trial

Rigel Pharmaceuticals Provides Update on COVID-19 Program
Published: 2021-08-13 (Crawled : 12:15) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology